Brazil health regulator cancels clinical study for Bharat Biotech vaccine
BRASILIA — Brazilian health regulator Anvisa on Monday said it had canceled a clinical study for the Covaxin vaccine for COVID-19 developed by India’s Bharat Biotech, amid allegations of irregularities in the government’s efforts to buy millions of doses of the shot.
Bharat on Friday said it had terminated a memorandum of understanding with the local partner company acting as its intermediary in Brazil, with Anvisa saying on Monday that the trials could not go forward as a result and would be canceled.
Anvisa had previously suspended the trials temporarily.
Subscribe to our daily newsletter
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.